Endometrial cancer generally has a good prognosis because most cases are diagnosed in stage I. It is possible to identify subgroups of patients with early-stage endometrial cancer with a poor prognosis. Despite a traditional generous use of adjuvant radiotherapy, these patients have five-year overall survival of approximately 80%. In this group there is a need for an effective systemic adjuvant therapy. Mainly based on superior response rates, doxorubicin + cisplatin was for many years the standard chemotherapy in endometrial cancer. Gynecologic Oncology Group (GOG)-177 was the first phase III study on chemotherapy in endometrial cancer that showed a survival advantage. Paclitaxel + doxorubicine + cisplatin was better than doxorubicine + cisplatin, but the toxicity of the three-drug regimen has precluded general acceptance. Paclitaxel + carboplatin has produced high response rates and is widely used, despite the lack of evidence based on randomised studies. GOG-122 compared doxorubicine + cisplatin with whole abdominal radiotherapy in advanced optimally operated endometrial cancer and showed that chemotherapy with doxorubicine + cisplatin resulted in superior survival. Two recent studies have compared adjuvant chemotherapy (cyclophosphamide + doxorubicine + cisplatin) with adjuvant radiotherapy in early-stage endometrial cancer. Both studies failed to show a difference between the treatments. Another study (NSGO-EC-9501/EORTC-55991) compared adjuvant radiotherapy plus chemotherapy with adjuvant radiotherapy, and showed better survival with the sequential combination.
Chemotherapy in Advanced or Recurrent Endometrial Cancer
Phase II studies on chemotherapy (CT) Currently, two large randomised studies with TcP in the experimental arm are running: GOG-209 and Japanese Gynecologic Oncology Group (JGOG)-2043. 13,14 It will be some years before we know the results.
Despite the lack of evidence based on randomised studies, TcP is considered by many as the de facto standard.
Gynecologic Oncology Group-122
GOG-122 was a pivotal study 15 
Randomised Studies on Adjuvant Chemotherapy in Early Endometrial Cancer
Gynecologic Oncology Group-34
The first randomised study (GOG-34) on the addition of adjuvant CT (doxorubicin) after RT in EC was initiated in the late 1970s. 16 The study has merely historical interest. It was terminated prematurely because of slow recruitment, and the authors concluded that the study was 
Finnish Study
A randomised Finnish study also tried to combine CT and RT in an unconventional way. 20 They gave split-course RT (2x28Gy separated by a pause of three weeks) (n=72). In the CT + RT arm (n=84), one course of cyclophosphamide 500mg/m 2 , epirubicin 60mg/m 2 and cisplatin 50mg/m 2 (CEP) was given before RT, one in between the RT courses and one after RT. Eligible patients had stage IA-B grade 3 or stage IC-IIIA grade 1-3. All patients underwent TAH-BSO and at least a pelvic lymphadenectomy was performed in 80% of the patients. The study was designed to detect a difference in OS of 20% with 60% survival in the RT group. However, no significant survival difference could be registered. The authors concluded that: "Age-adjusted sequential radio-and CT compared to radiotherapy alone did not alter the risk of death: HR 1.21 (95% CI 0.56-2.65)". The study was not powered to detect equality, and it is not appropriate to state that there is no difference -the result is consistent with the possibility that RT + CT was 44% better or 165% worse than RT alone.
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Radiation Therapy Oncology Group-9708
The Radiation Therapy Oncology Group (RTOG) performed a pilot study (RTOG-9708) 22 combining adjuvant pelvic RT (45Gy + VBT) with concomitant cisplatin (50mg/m 2 ) on days one and 28 (RT-CT) followed by four courses of paclitaxel (175mg/m 2 ) and cisplatin (50mg/m 2 ) at four-week intervals. Patients with grade two or three endometrial adenocarcinoma with either >50% MI, cervical stromal invasion or pelvic-confined extrauterine disease were eligible. This treatment was feasible with excellent loco-regional control, suggesting additional effects of CT and radiation. Distant metastases continued to occur in more advanced staged patients.
Post-operative Radiation Therapy for Endometrial Carcinoma-3
The Postoperative Radiation Therapy for Endometrial Carcinoma (PORTEC) group has started an international randomised study (PORTEC-3) with the RTOG concept. 
Discussion
There is one study showing superiority of CT over WART. 15 However, this study is not a pure study of adjuvant therapy because it was performed on a mixture of patients with no residual post-operative tumour and patients with remaining residuals. The RT was WART, which is not normally used in the adjuvant situation in early-stage EC.
Two fairly big randomised studies have failed to show differences in OS or PFS between CT and RT. 17, 18 Neither of these trials was designed or dimensioned to show non-inferiority, which actually means that they are inconclusive. 
